CoChat

Voltage-Gated Sodium Channels: Structure, Function, Pharmacology, and Clinical Indications

Open access
de Lera Ruiz, Manuel, Kraus, Richard L. · 2015 · Journal of Medicinal Chemistry

The DOI matches its Crossref record; 186 of the 203 references it cites were found in a registry or an index.

Abstract

The tremendous therapeutic potential of voltage-gated sodium channels (Navs) has been the subject of many studies in the past and is of intense interest today. Nav1.7 channels in particular have received much attention recently because of strong genetic validation of their involvement in nociception. Here we summarize the current status of research in the Nav field and present the most relevant recent developments with respect to the molecular structure, general physiology, and pharmacology of distinct Nav channel subtypes. We discuss Nav channel ligands such as small molecules, toxins isolated from animal venoms, and the recently identified Nav1.7-selective antibody. Furthermore, we review eight characterized ligand binding sites on the Nav channel α subunit. Finally, we examine possible therapeutic applications of Nav ligands and provide an update on current clinical studies.

Overview

Integrity signals

Registry

Crossref · 10.1021/jm501981g

Cites

186 of 186 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

1 retracted

Show all 186 references

Research works printed but not linked: 6

  1. Nardi, 2012, Advances in targeting voltage-gated sodium channels with small molecules, ChemMedChem, 7, 1
  2. Moreau, 2014, Biophysics, pathophysiology, and pharmacology of ion channel gating pores, Front. Pharmacol., 3, 5
  3. Cestèle, 2013, Nonfunctional Nav1.1 familial hemiplegic migraine mutant transformed into gain of function by partial rescue of folding defects, Proc. Natl. Acad. Sci. U. S. A., 110, 17546, 10.1073/pnas.1309827110 · DOI
  4. (a) Convergence Pharmaceuticals’ Novel Nav1.7 Selective Sodium Channel Blocker CNV1014802 Demonstrates Proof of Concept in Second Neuropathic Pain Study in Lumbosacral Radiculopathy; Convergence Pharmaceuticals: Cambridge, UK, Sept23, 2014; http://www.convergencepharma.com/userfiles/file/140923_LSR_FINAL.pdf, (accessed Mar 20, 2015).
  5. (b) The Pipeline; Convergence Pharmaceuticals: Cambridge, UK, 2015; http://www.convergencepharma.com/?page_id=16, (accessed Mar 20, 2015).
  6. Kwong, 2013, Pharmacological Characterization Of GSK2339345, A Novel Voltage-Gated Sodium Channel Blocker For The Symptomatic Relief Of Cough, Am J. Resp. Crit. Care Med., 187, A4936

Cited by

Items 201–300 of 603

Metadata

Authors
de Lera Ruiz, M., & Kraus, R. L.
Affiliations
  • Merck Research Laboratories , 770 Sumneytown Pike , , ,
  • Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
Venue
Journal of Medicinal Chemistry
Published
2015-04-30
Volume
58
Issue
18
Pages
7093-7118
ISSN
  • 0022-2623 (ISSN-L)
  • 1520-4804
OpenAlex
W2031713143
Cited by
548
References
203
Citations by year
2026: 42 · 2025: 58 · 2024: 70 · 2023: 80 · 2022: 71 · 2021: 50 · 2020: 39 · 2019: 37 · 2018: 40 · 2017: 33 · 2016: 20 · 2015: 8
FWCI
3.36
Type
journal article
Language
en
Open access
Locations
  • Journal of Medicinal Chemistry (publishedVersion, other-oa)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ion channel regulation and function
  • Life Sciences › Neuroscience › Sensory Systems › Ion Channels and Receptors
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
Keywords
voltage-gated sodium channels, Nav1.7, sodium channel structure, sodium channel toxins, ligand binding sites, nociception, pain
MeSH terms
Animals, Biological Products, Cardiovascular Diseases, Clinical Trials as Topic, Drug Industry, Epilepsy, Humans, Ligands, Mutation, Neoplasms, Neuromuscular Diseases, Pain, Respiratory Tract Diseases, Ion Channel Gating, Protein Structure, Tertiary, Protein Subunits, Channelopathies, Voltage-Gated Sodium Channels, Voltage-Gated Sodium Channel Blockers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.